A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension

Completed · Phase 2

Conditions studied: Hypertension, Pulmonary

In brief

Rationale: Idiopathic pulmonary arterial hypertension (IPAH) is characterized by in situ thrombosis and increased thromboxane A2 (Tx-M) synthesis. While both may be attributable to abnormal platelet function, there are no studies of anti-platelet therapy in IPAH. Objectives: The purpose of this study is to assess the effects of aspirin (ASA) and clopidogrel on platelet function and eicosanoid metabolism in patients with IPAH.

Key facts

Study ID

NCT00105209

Run by

Kawut, Steven, MD

People needed

20

Starts

2002-04-01

Expected to finish

2003-12-01

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of IPAH
• ≥ 18 years of age
• NYHA functional class I, II, or III
• Clinical stability (i.e., without change in pulmonary arterial hypertension medical regimen within one month prior to enrollment).

You may not qualify if…

• Other forms of PAH
• A contraindication to ASA or clopidogrel
• Thrombocytopenia (defined as platelet count ≤ 75,000)
• History of intracranial hemorrhage or chronic thromboembolic disease
• Renal failure
• Inability or unwillingness to avoid non-steroidal anti-inflammatory agents, ASA, or warfarin use for the duration of the trial

Where it is running

• Columbia University College of Physicians and Surgeons — New York, New York, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.